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1. Introduction 
Combination therapy with Cyclosporin A (CyA) and steroids has improved the course 
of patients after cadaveric renal transplantation. Application of this therapeutic 
advance to the transplantation of cadaveric livers and hearts was a natural extension 
to be described in this communication. 
2. Liver transplantation 
29 patients were accepted for the clinical trial for the indications listed in Table 1. 
8 of the recipients were in the pediatric age group (2-16 years) and the other 2 I 
were 20-56 years old. The liver grafts were preserved with Collins solution for 1 ~-
T ABLE I: Diagnoses in 29 liver recipients accepted for clinical trial 
OIronic active hepatitis 
"nmary hepatic malignancy 
(3 hepatoma, one intrahepatic duct cell carcinoma) 
.&WIY atresia 
Ivdd -C'hiari Syndrome 
Secondary biliary cirrhosis 
P'runOiIY biliary cirrhosis 
pckro~in~ cholangitis 
lone with duct cell carcinoma) 
Illel" Syndrome 
Alph;a·I·antitrypsin deficiency and cirrhosis 
hepatic cirrhosis 
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104- h and transplanted by the same techniques as have been used in the ~a_pcaffK 
1969; Starzl et al., 1979). 
Donor recipient matching for HLA antigens was random. Because of urgent ..... 
two donors were accepted in spite of ABO incompatibility (A to 0 and A to I), II 
three more cases, a positive cross match was present with complete kiJIing of ~ 
lymphocytes by pre-existing cytotoxic antibodies in the recipient serum. It is k~ 
(Starzl et al., 1979) that the liver is resistant to hyperacute rejection from prefontll4 
antibody states. 
Cy A usually was started a few hours preoperatively at 17.5 mg/kg and .:ontinliM 
daily, usually with half the dose every 12 h. The quantities were reduced subsequently 
if toxic manifestations developed, of which suspected nephrotoxicity (Fig. I) wu the 
most important. 
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Fig. 1. Cy A and steroid therapy in a woman with a hepatoma whose cirrhosis was too severe to 
permit subtotal hepatic resection. Note the 5 day initial burst of prednisone therapy, and the 
adjustment ofCyA dose as the BUN rose. 
In the Colorado part of the series, steroids were not given at first in half of the 
cases. When it became evident from clinical observations and biopsy evidence that 
rejection was common, steroids were begun on the day of operation. Adult patients 
who did not have profound metabolic abnormalities and who left the operating room 
in good condition were given the 5 day burst of prednisone described elsewhere in this 
symposium for renal recipients, starting at 200 mg and stopping with a maintenance of 
20 mg per day (Fig. I). Initial and maintenance therapy were scaled down in infants 
and children. If the patient was in poor condition, high dose initial therapy with ster-
oids was omitted (Fig. 2). 
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The 14 patients were operated upon between March and September 1980. Two reci-
pients died on the operating table (Table 2) from technical complications and were 
not treated with immunosuppression. One of the remaining 12 died 19 days post-
operatively of hepatic artery thrombosis. 
All of the other 11 patients lived through the first post-operative year. Including 
the two intra-operative deaths, the one year survival was 78.6%, and excluding them, 
the one year survival was 92%. Many complications which were treated successfully 
(Starzl et ai., 1 98la,b ) were the kind which had been almost always lethal under con-
ventional immunosuppression (Starzl et ai., 1969, 1979). The ability to maintain good 
graft function despite low-dose steroid therapy was the distinguishing feature of the 
CyA series. 
Two patients died after a year (12 and 16 months). One had recurrence of a cholan-
giocarcinoma from her native liver, and the other from recurrent Budd-Chiari syn-
drome. Nine (64.3%) of the original 14 patients are still alive after 1-1 t years, and all 
but one have iI-ormal or near normal liver function. Of those 12 actually treated with 
CyA and prednisone, the present survival is 75%. 
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,.. 2. Omission of steroid burst therapy in a H)-year-old boy who was thOUght to be at increased 
.. of pulmonary infection because of a recent gastrointestinal haemorrhage. He was transferred 
.. lilt University of Pittsburgh from the Intensive Care Unit of a hospital in a distant city. The full 
... of Cy A has been well tolerated, 
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TABLE 2: Causes of death in Denver series of liver transplantations in CyA era (\4 p~f~"D" 
Operative 
Hepatic artery thrombosis (19 days) 
Recurrent malignancy (12 months) 
Recurrent Budd-Chiari Syndrome (16 months) 
• Not treated with immunosuppression. 
TABLE 3: Causes of death in Pittsburgh Series (15 patients) 
Poorly preserved livers 
(with technical errors 
(without technical errors 
Systemic aspergillosis 
2.2. Pittsburgh series 
2' 
4 
2) 
2) 
1 
15 patients were accepted for the trial. The first 4 (all adults) died after 4 to 16 days 
(Table 3). A feature common to these consecutive disasters was poor initial liver fun~· 
tion including failure of clotting; technical errors in biliary tract reconstruction were 
also committed in two. Multiple organ failure and uncontrollable infections ensued. At 
autopsy, the livers had widespread necrosis but little or no evidence of rejection. 
A deviation had been made from the previously standardized harvesting procedure 
leading to de.emphasis or omission of cooling by the portal venous route, and reliance 
on in situ hepatic arterial cooling. 
After correction of this error, uniformly adequate livers were obtained and 10 of 
the next II recipients have survived for 1-4~ months. All but one have been discharged 
from the hospital, including a child whose first liver was replaced with another graft 
after two weeks because of a huge Candida abscess which destroyed much of the 
right lobe. The only death in the last 11 cases was from disseminated aspergillosis at 
8 days in a patient who was in Stage 4 hepatic coma prior to operation. Liver function 
is normal or near normal in the 10 survivors. 
Nephrotoxicity of Cy A in liver recipients has been studied by Klintmalm et al. 
(1981). Renal dysfunction was usually correctable by downward adjustments of CyA 
dosage. However, one patient required hemodialysis. No examples of CyA hepatotoxi· 
city have been recognized. 
2.3. Actuarial survival in combined series 
Even including the two operative deaths in the Colorado series and the four flawed 
cases in the Pittsburgh series, the one year life expectancy has been raised to better 
than 70% in the CyA era, twice as high as in our previous total experience (Fig. 3). 
Caine et a1. (1981) have reported a similar recent improvement corresponding to their 
use of CyA. Calne et al. (1979) were the first to use eyA in clinical liver transplanta· 
tion. 
LIVER TRANSPL 
___ CYCLe 
...---. HISle;: 
0<005 
MONTHS POST·TR; 
fig. 3. One year actuari, 
uyra"p~ratively and 4 \\ 
ye31 survival of histoIlCal 
3. Cardiac transp/u 
The University of Pit 
formed 7 heart tran 
late july 1981. Beca 
function could be ae 
depicted in Fig. 1 in 
These cases, inch 
ratelv. 6 of the 7 re 
Efro~ infection and 
serum contained an 
was not known abo 
was badly damaged. 
4. Discussion and 
The grafting of org, 
transplantation, in 
cial kidney did not 
ably as has been n 
extra renal organs' 
principles of immu 
edly be applicable t 
--- ,- ----------T---
er"tl4l'illlenlsl \ 
2· 
1 
4 
2) 
2) 
I 
lfter 4 to 16 days 
. initial liver fune-
onstruction were 
:tions ensued. At 
rejection. 
'esling procedure 
'ute, and relian" 
: ained and 10 of 
~ been discharged 
ith another graft 
ed much of the 
J aspergillusi) at 
1. Liver function 
~lintmalm et aI. 
lstments of (yA 
:yA hepatoloU-
the four flav.·td 
raised to ben~ 
'rience (F is, 3). 
londing to thnr 
ver transplan" 
I 
435 
LIVER TRANSPLANT 
--. CVClOSPQRIN A ~KK" 291 
.-..-.. HISTORICAL CONTROLS In' 170) 
40 
20 p<OOl 
6 '2 
MONTHS POST· TRANSPLANT 
Fig. 3. One year actuarial life survival curve of the last 29 liver recipients, including two who died 
intraoperatively and 4 who received livers that were damaged by poor preservation. The actual one 
year survival of historical con trois also is shown, 
3. Cardiac transplantation 
The University of Pittsburgh cardiac transplantation team (H. B. B., R. H., B. G.) per-
formed 7 heart transplantations under Cy A and steroid therapy from early April to 
late July 1981, Because no interval, however brief, of rejection and ineffective cardiac 
function could be accepted, the steroid withdrawal was done more gradually than that 
depicted in Fig. 1 in a liver recipient. 
These cases, including their special management problems, will be reported sepa-
rately. 6 of the 7 recipients (all adults) are alive after 1~-R months. The only death 
(from infection and heart failure) was at 10 weeks of a 48-year-old woman whose 
serum contained anti-donor T warm cytotoxic antibodies. The positive crossmatch 
was not known about in advance. Although the heart escaped hyperacute rejection, it 
was badly damaged. 
4. Discussion and Conclusions 
Tht grafting of organs such as liver and heart has not had the wide application of renal 
transplantation, in part because artificial life support systems analogous to the artifi-
calltidney did not and do not exist. With the ability to control rejection more predict-
Ibl)' as has been made possible with Cy A and steroids, interest in transplantation of 
otra renal organs will surge. Although each organ will have special requirements, the 
pnnciples of immunosuppression evolved with the simple kidney model will undoubt-
.. tdIy be applicable to all. 
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